• FT reports that Pfizer will soon announce the takeover of Metsera
• Upfront cost $47.5/share = ~$5bn
• Milestone payments of another $22.5/shr would bring the total to $7.3bn
• Pfizer currently generates around $12.5bn in Free Cash Flow and has $13+bn of cash on the balance sheet so funding would not be a major issue.
• Leverage would increase by only 0.2x initially.
• The deal would potentially give Pfizer access to a novel form of weight-loss treatment with fewer negatives compared to existing GLP-1 blockers which lead to muscle loss.
Find more articles and bullets on these widgets:
As with Deutsche earlier, NatWest has changed its Fed call after the Powell Jackson Hole speech to reflect a 25bp September cut. Previously, the call was for no cuts in 2025. The new baseline outlook includes further 25bp cuts in December and March, bringing rates closer to neutral ("however, the changing composition of the committee becomes far less clear once Powell term expires in May").
Gains this week in USDCAD and the breach of resistance at 1.3879, the Aug 1 high, marked a positive development, however the slippage into the Friday close undermines this sentiment - for now. Moving average studies have crossed and are in a bull-mode position, reinforcing current conditions. An extension higher would signal scope for a climb towards 1.4019, a Fibonacci retracement. On the downside, support to watch lies at 1.3769, the 50-day EMA - a level not yet challenged by the correction lower.
The June retail sales release helps wrap up the last major data before Canadian Q2 GDP is released on Friday August 29.
